Effect of NT-proBNP Guided Treatment of Chronic Heart Failure
NCT ID: NCT00149422
Last Updated: 2010-02-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
INTERVENTIONAL
2004-06-30
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NT-proBNP in Acute Dyspnea: Effects on Treatment, Hospitalisation and Costs
NCT00410293
The Influence of Beta Blocker Therapy on the Hemodynamic Response to Inotrope Infusion in Patients With Acute Decompensated Heart Failure
NCT01971944
Clinical Assessment of the Treatment With Cardiac Sympathetic Blockade on Chronic Heart Failure
NCT02391142
Effects of Cardiac Sympathetic Blockade in Patients With Chronic Heart Failure
NCT02282618
Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction
NCT05168462
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NT-proBNP guided treatment group
In this group, management was guided by an individually set NT-proBNP, defined by the lowest level at discharge or 2 weeks thereafter. If NT-proBNP levels were elevated above the individually set NT-proBNP interventions were performed according to the ESC heart failure guidelines.
NT-proBNP measurements
Clinically guided arm
Heart failure treatment guided by clinical assessment.
NT-proBNP measurements
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NT-proBNP measurements
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Elevated NT-proBNP levels on admission
Exclusion Criteria
* Urgent intervention
* Severe lung disease
* Presence of life threatening disease
* Signed informed consent for other study
* Mental or physical status not allowing written informed consent.
* Unwillingness to give informed consent
* Patients undergoing haemodialysis or continuous ambulatory peritoneal dialysis (CAPD)
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Interuniversity Cardiology Institute of the Netherlands
OTHER_GOV
Netherlands Heart Foundation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Academic Medical Center, Amsterdam
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dave JW van Kraaij, MD
Role: PRINCIPAL_INVESTIGATOR
Maastricht University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universtiy Hospital Maastricht
Maastricht, Limburg, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Eurlings LW, van Pol PE, Kok WE, van Wijk S, Lodewijks-van der Bolt C, Balk AH, Lok DJ, Crijns HJ, van Kraaij DJ, de Jonge N, Meeder JG, Prins M, Pinto YM. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol. 2010 Dec 14;56(25):2090-100. doi: 10.1016/j.jacc.2010.07.030.
Related Links
Access external resources that provide additional context or updates about the study.
Interview PRIMA-study ACC congress Orlando 2009
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2003B131
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.